Monday, December 23, 2024

Enable Medicine Appoints Kamni Vijay as Chief Executive Officer

Related stories

Doc.com Expands AI developments to Revolutionize Healthcare Access

Doc.com, a pioneering healthcare technology company, proudly announces the development...

Amesite Announces AI-Powered NurseMagic™ Growth in Marketing Reach to Key Markets

Amesite Inc., creator of the AI-powered NurseMagic™ app, announces...

Quantiphi Joins AWS Generative AI Partner Innovation Alliance

Quantiphi, an AI-first digital engineering company, has been named...
spot_imgspot_img

Enable Medicine, a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer. She succeeds co-founder Sunil Bodapati, who developed Enable Medicine’s strategy and closed Series A financing in 2022. Mr. Bodapati remains Chairman of the Board and will transition to the role of Chief Strategy Officer.

“I’m excited to join Enable Medicine, at this pivotal moment in the biopharmaceutical industry, as drug discovery and development are powered by the convergence of technology and biotechnology. Together with our dedicated team, we will empower the scientific community to answer some of biology’s most intractable questions, delivering best in class insights from our atlases. I look forward to working with our scientific and engineering teams, senior leadership and partners to help advance our leadership position in AI for biological research and drug discovery,” said Kamni Vijay.

Dr. Vijay brings more than 25 years of experience in the life sciences and diagnostics industries. As Vice President and General Manager at Becton Dickinson, she was responsible for the company’s product development and commercialization efforts in point of care diagnostics, leading their participation in at-home and point of care testing to support the COVID-19 pandemic response. Dr. Vijay was previously the Vice President and General Manager of Bio-Techne’s emerging Spatial Biology business. Under her leadership, Bio-Techne rose to become a leading provider of spatial transcriptomic reagents and services under the Advanced Cell Diagnostics brand. Earlier in her career, Dr. Vijay held senior positions at Agilent Technologies, where she drove the advancement of Agilent’s participation in the next generation sequencing market, and at Bio-Rad Laboratories where she partnered to establish wide-scale commercial application of the Polymerase Chain Reaction (PCR) and qPCR technologies in the research and diagnostic fields. Her scientific training in Biochemistry and Molecular Biology began at Dartmouth College, and continued throughout her PhD and post-doctoral studies at UC Davis where her research was extramurally funded by the NIH within Molecular and Cellular Biology program.

Also Read: BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

“Kamni Vijay is highly respected in the life sciences and diagnostics industries,” said Elena Viboch, Partner at General Catalyst. “We believe Kamni’s expertise uniquely qualifies her to spearhead Enable Medicine’s mission of accelerating research and bringing innovative medicines to patients.”

Kamni has successfully driven high velocity growth and scientific rigor in multiple organizations to accelerate discovery and improve patient outcomes. “Kamni brings to Enable extensive experience leading high-performing teams and is exactly the type of leader Enable needs as we advance into our next phase of growth,” said Sunil Bodapati, Chairman and Co-Founder, Enable Medicine. “She will be an incredible leader for Enable, to build our next generation BIOS platform for drug discovery and healthcare leveraging multimodal biological data and AI. I look forward to continued engagement in the business and am pleased to partner with Kamni.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img